tiprankstipranks
Medexus Pharmaceuticals Inc (TSE:MDP)
TSX:MDP
Canadian Market
MDP
Medexus Pharmaceuticals Inc
RESEARCH TOOLSreports
Want to see TSE:MDP full AI Analyst Report?

Medexus Pharmaceuticals Inc (MDP) Stock Forecast & Price Target

67 Followers
See the Price Targets and Ratings of:

MDP Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Medexus
Pharmaceuticals Inc
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

MDP Stock 12 Month Forecast

There Are No Analyst Ratings for TSE:MDP In The Last 3 Months.
Highest Price Target―Average Price Target―Lowest Price Target―
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

MDP Financial Forecast

MDP Earnings Forecast

Next quarter’s earnings estimate for MDP is -C$0.02 with a range of -C$0.03 to C$0.00. The previous quarter’s EPS was C$0.00. MDP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year MDP has Performed in-line its overall industry.
Next quarter’s earnings estimate for MDP is -C$0.02 with a range of -C$0.03 to C$0.00. The previous quarter’s EPS was C$0.00. MDP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year MDP has Performed in-line its overall industry.

MDP Sales Forecast

Next quarter’s sales forecast for MDP is C$35.18M with a range of C$34.67M to C$35.90M. The previous quarter’s sales results were C$35.31M. MDP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year MDP has Performed in-line its overall industry.
Next quarter’s sales forecast for MDP is C$35.18M with a range of C$34.67M to C$35.90M. The previous quarter’s sales results were C$35.31M. MDP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year MDP has Performed in-line its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bloom Burton Analyst forecast on TSE:MDP
David Martin PhD
Bloom Burton
Bloom Burton
C$6
Buy
51.13%
Upside
Reiterated
02/13/26
Medexus Pharmaceuticals: Channel Headwinds Masking Demand as Strategic Positioning Supports Buy-Rated Risk‑Reward
Raymond James Analyst forecast on TSE:MDP
Michael W. Freeman
Raymond James
Raymond James
C$8
Buy
101.51%
Upside
Reiterated
08/14/25
Raymond James Sticks to Its Buy Rating for Medexus Pharmaceuticals Inc (MDP)
Canaccord Genuity Analyst forecast on TSE:MDP
Unknown Analyst
Canaccord Genuity
Not Ranked
Canaccord Genuity
C$6
Buy
51.13%
Upside
Reiterated
06/26/25
Canaccord Genuity Reaffirms Their Buy Rating on Medexus Pharmaceuticals Inc (MDP)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bloom Burton Analyst forecast on TSE:MDP
David Martin PhD
Bloom Burton
Bloom Burton
C$6
Buy
51.13%
Upside
Reiterated
02/13/26
Medexus Pharmaceuticals: Channel Headwinds Masking Demand as Strategic Positioning Supports Buy-Rated Risk‑Reward
Raymond James Analyst forecast on TSE:MDP
Michael W. Freeman
Raymond James
Raymond James
C$8
Buy
101.51%
Upside
Reiterated
08/14/25
Raymond James Sticks to Its Buy Rating for Medexus Pharmaceuticals Inc (MDP)
Canaccord Genuity Analyst forecast on TSE:MDP
Unknown Analyst
Canaccord Genuity
Not Ranked
Canaccord Genuity
C$6
Buy
51.13%
Upside
Reiterated
06/26/25
Canaccord Genuity Reaffirms Their Buy Rating on Medexus Pharmaceuticals Inc (MDP)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Medexus Pharmaceuticals Inc

3 Months
David Martin PhDBloom Burton
Success Rate
5/11 ratings generated profit
45%
Average Return
+9.41%
Copying David Martin PhD's trades and holding each position for 3 Months would result in 45.45% of your transactions generating a profit, with an average return of +9.41% per trade.
1 Year
David Martin PhDBloom Burton
Success Rate
10/11 ratings generated profit
91%
Average Return
+37.74%
Copying David Martin PhD's trades and holding each position for 1 Year would result in 90.91% of your transactions generating a profit, with an average return of +37.74% per trade.
2 Years
David Martin PhDBloom Burton
Success Rate
11/11 ratings generated profit
100%
Average Return
+60.52%
Copying David Martin PhD's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +60.52% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MDP Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
1
1
1
1
0
Buy
0
0
0
0
0
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
1
1
1
1
0
In the current month, MDP has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MDP average Analyst price target in the past 3 months is ―.
Each month's total comprises the sum of three months' worth of ratings.

MDP Stock Forecast FAQ

What is TSE:MDP’s average 12-month price target, according to analysts?
Currently, no data Available
What is TSE:MDP’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for TSE:MDP, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is TSE:MDP a Buy, Sell or Hold?
      Currently, no data Available
      What is Medexus Pharmaceuticals Inc’s price target?
      Currently, no data Available
      What do analysts say about Medexus Pharmaceuticals Inc?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of TSE:MDP?
      Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.